Ryan Rader, M.D., F.A.C.P.

Professional Background

Ryan Rader, MD, is a Clinical Assistant Professor of Medicine at the University of Kansas Medical Center. Dr. Rader received his medical degree from the University of Missouri School of Medicine in Columbia, MO. He completed his internal medicine residency at the Cleveland Clinic and Hematology/Oncology fellowship at Duke University. He is board certified in Internal Medicine, Hematology, and Medical Oncology.

His clinical interest focuses on the treatment of Breast Cancer. He serves as the Vice Chair of the Breast Cancer Disease Working Group at the University of Kansas Cancer Center.

He also serves on the Hematology and Oncology Fellowship Program Evaluation Committee.

Dr. Rader practices at the University of Kansas Cancer Center in Lee’s Summit and is on staff at several community hospitals.

• BS, Chemistry with an Emphasis in Pre-Medicine; Biological Sciences, Missouri University of Science & Technology (Rolla, Missouri), Rolla, Missouri
• MD, MD, University of Missouri School of Medicine (Columbia, Missouri), Columbia, Missouri
• Internship, Internal Medicine, Cleveland Clinic Foundation (Cleveland, Ohio), Cleveland, Ohio
• Residency, Internal Medicine, Cleveland Clinic Foundation (Cleveland, Ohio), Cleveland, Ohio

• Hematology, American Board of Internal Medicine
• Internal Medicine, American Board of Internal Medicine
• Medical Oncology, American Board of Internal Medicine

• American Society of Clinical Oncology, Member, 2020 - Present
• American College of Physicians, Member, 2017 - Present

---

• Rader RK, Anders CK, Lin NU, Sammons SL. 2023. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.. Current treatment options in oncology, 24 (6), 611-627
• Dent S, Rader RK, White O, Patterson B, Moore HN. 2024. Moving beyond cardiotoxicity detection to prevention: A pharmacologic review. Current Treatment Options in Cardiovascular Medicine, 26, 1-12
• Stecklein ShaneR., Aripoli Allison, Salgado Roberto, O'Dea Anne, Nye LaurenElizabeth, Larson KelseyE., Satelli Deepti, Rader Ryan, Madan Rashna, Yoder Rachel, Staley JoshuaM., Fernandez India, Heinrich Adam, Wagner JamieL., Balanoff Christa, Kilgore Lyndsey, Bantis Leonidas, Godwin AndrewK., Khan QamarJ., Sharma Priyanka. 2024. NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 42 (16_suppl), TPS629-TPS629. https://doi.org/10.1200/jco.2024.42.16_suppl.tps629
• Nizam A, Rader RK, Tzeng A, Wei W, Sheng I.Y.-F., Martin A, Wee CE, Gilligan TG, Gupta S, Ornstein MC. 2023. Safety and efficacy outcomes in immune checkpoint inhibitor-treated patients with metastatic urothelial carcinoma requiring treatment interruption or discontinuation due to immune-related adverse events. Clinical Genitourinary Cancer, 22 (2), 368-379
• Gvazava Nanuli, Stevens ToddM, Rader RyanK. 2025. A Case of Tumor-to-Tumor Metastasis: Breast Carcinoma Metastatic to Oncocytic Carcinoma of Thyroid. Kansas Journal of Medicine, 18, 47-49
• Im Cindy, Hasan Hasibul, Stene Emily, Monick Sarah, Rader RyanK, Sheade Jori, Wolfe Heather, Lu Zhanni, Spector LoganG., McDonald AaronJ, Nolan Vikki, Arnold MichaelA. , Conces Miriam, Moskowitz ChayaS., Henderson TaraO., Robison LeslieL., Armstrong GregoryT., Yasui Yutaka, Nanda Rita, Oeffinger KevinC., Neglia JosephP., Blaes Anne, Turcotte LucieM.. 2025. Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer. Nature Communications, 16 (1), 3088. https://www.nature.com/articles/s41467-025-58434-w